Allergy & Immunology

Eosinophilic Disorders

Questions discussed in this category

What is your approach to biologic selection in a patient with resistant/persistent ABPA?

How would you approach an asymptomatic older female patient with eosinophilia to 17,000, present for years, and normal eosinophilia workup including marrow and negative FLIP1?

Would you treat a patient like this with Nucala and if so, what would be your marker of success?

1 Answer available

Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?

1 Answer available

What treatment options do you consider if eosinophilia with end organ dysfunction persists with q8 week dosing of benralizumab and you can't obtain approval for q4 week dosing?

1 Answer available

What parasites do you screen for in your workup of HES?

1 Answer available

How often do you monitor the eosinophil count after initiating anti-IL5 therapy for HAE?

1 Answer available

Would you favor treating HES manifesting with EoE with dupilumab or anti-IL5 therapy?

1 Answer available

What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?

2 Answers available

How do you approach an isolated T-cell gene arrangement found in the setting of persistent hypereosinophilia?

If all work-up including peripheral flow, bone marrow biopsy, PET-CT returns negative, what additional management (if any) would be recommended?

1 Answer available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

The New England journal of medicine, 2017-05-18

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

European journal of haematology, 2017-04

J Allergy Clin Immunol Pract, 2021 Feb 03

CD3CD4 Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited.

Eur J Haematol, 2020 May 18

Causes of hypereosinophilia in 100 consecutive patients.

Br J Haematol, 2019 Nov 13

Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.

Br J Haematol, 2021 Jun 08

Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.

Allergy & Immunology

Eosinophilic Disorders

Questions discussed in this category

Papers discussed in this category

Related Topics in Allergy & Immunology